Zuclopenthixol acetate for acute schizophrenia and similar major mental illnesses.
Kaushadh Jayakody, Sarah Chuang, Shalmini Gunadasa et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness of zuclopenthixol acetate for managing acute behavioral disturbances in 714 participants with acute schizophrenia and similar major mental illnesses. Compared to standard treatments, the findings suggest that zuclopenthixol acetate may lead to fewer participants being sedated at 24 hours (RR 0.25, CI 0.11 to 0.54; P < 0.001).
Key findings
- Zuclopenthixol acetate may not differ from standard medications in sedation rates at two hours (RR 0.60, CI 0.27 to 1.34).
- At 15 minutes, more participants were sedated with haloperidol plus promethazine than with zuclopenthixol acetate (RR 1.31, CI 1.06 to 1.63; P = 0.01).
- At 24 hours, zuclopenthixol acetate resulted in fewer participants sedated compared to standard treatments (RR 0.25, CI 0.11 to 0.54; P < 0.001).
Why it matters
Understanding the effectiveness of zuclopenthixol acetate in acute settings is crucial for clinicians managing aggressive or agitated patients with schizophrenia, as it may influence treatment choices and patient outcomes.
What to keep in mind
The certainty of evidence ranged from moderate to very low, and selective reporting was identified in 10 of the 11 included studies.